PCL, Inc.

Equities

A241820

KR7241820000

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 03:30:00 24/06/2024 am IST			5-day change	1st Jan Change
1,000 ^KRW	+0.20%		+3.95%	-72.11%

16/01	PCL, Inc. announced that it has received KRW 9.99999885 billion in funding from Global Emerging Markets	CI
2023	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from Global Emerging Markets	CI

PCL, Inc. has filed an IPO in the amount of KRW 21.6 billion.

January 12, 2017 at 10:30 am IST

PCL, Inc. has filed an IPO in the amount of KRW 21.6 billion.

Security Name: Shares
Security Type: Common Stock
Securities Offered: 1,500,000
PriceRange: KRW 11300 to KRW 14400
Discount Per Security: KRW 720

Transaction Features: Sponsor Backed Offering

Latest news about PCL, Inc.

PCL, Inc. announced that it has received KRW 9.99999885 billion in funding from Global Emerging Markets	16/01	CI
PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from Global Emerging Markets	26/12	CI
PCL, Inc. announced that it expects to receive KRW 9.99999885 billion in funding from Global Emerging Markets	21/12	CI
PCL, Inc. announced that it expects to receive KRW 9.99999838 billion in funding from Global Emerging Markets	15/12	CI
South Korean Stocks Close Lower as Uncertainties Around US Debt Ceiling Deal Remain; PCL Loses 13%	31/23/31	MT
PCL to Raise 36 Billion Won via Share Issuance	31/23/31	MT
PCL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23/23/23	CI
PCL, Inc. announced that it has received KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd.	29/22/29	CI
PCL to Raise 3 Billion Won via Share Issuance; Shares Jump 4%	22/22/22	MT
PCL, Inc. announced that it expects to receive KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd.	21/22/21	CI
PCL, Inc. terminated the acquisition of 40.76% stake in mCureX Therapeutics, Inc. from OliX Pharmaceuticals, Inc, Samyang Holdings Corporation, AJU Good Growth Support Fund managed by Aju IB Investment Co., Ltd. and Kiwoom New Hero Fund I managed by Kiwoom Investment Co., Ltd.	12/22/12	CI
PCL, Inc. announced that it has received KRW 12.060247575 billion in funding	12/22/12	CI
OliX Pharmaceuticals, Inc agreed to acquire 6.63% stake in PCL, Inc. for KRW8.04 billion.	11/22/11	CI
PCL, Inc. agreed to acquire unknown minority stake in stake in mCureX Therapeutics, Inc. from OliX Pharmaceuticals, Inc, Samyang Holdings Corporation, AJU Good Growth Support Fund managed by Aju IB Investment Co., Ltd. and Kiwoom New Hero Fund I managed by Kiwoom Investment Co., Ltd. for KRW12.2 billion.	11/22/11	CI
PCL, Inc.(KOSDAQ:A241820) dropped from S&P Global BMI Index	07/22/07	CI
PCL, Inc.(KOSDAQ:A241820) added to S&P Global BMI Index	20/21/20	CI
MCureX Therapeutics, Inc. announced that it expects to receive KRW 2 billion in funding from OliX Pharmaceuticals,Inc, PCL, Inc., Samyang Holdings Corporation	23/21/23	CI
PCL, Inc. announced that it has received KRW 40.499938368 billion in funding from a group of investors	25/21/25	CI
Datametrex AI Limited Secures Authorization by Health Canada for PCL Inc.'s COVID19 Rapid Antigen Test Kit	23/21/23	CI
PCL, Inc. announced that it expects to receive KRW 40.499938368 billion in funding from a group of investors	18/21/18	CI
Datametrex AI Limited Announces Submission of a Medical Devices Interim Order Request Form to Approve PCL, Inc.’s COV05 COVID19 Rapid Antigen Detection Kits to Health Canada	01/20/01	CI
Datametrex AI Limited Secures Rights to Sell and Distribute Pcl, Inc.’s COV05 COVID19 Rapid Antigen Detection Kits	12/20/12	CI
PCL, Inc. announced that it has received KRW 9.999993558 billion in funding from Korea Investment Partners Co. Ltd.	31/19/31	CI
PCL, Inc. announced that it expects to receive KRW 9.999993558 billion in funding from Korea Investment Partners Co. Ltd.	23/19/23	CI
PCL, Inc. has completed an IPO in the amount of KRW 12 billion.	17/17/17	CI

Chart PCL, Inc.

Duration

Period

More charts

Company Profile

PCL Inc. is a Korea-based company principally engaged in development and manufacture of vitro diagnostic medical device for immunological diagnosis. The Companyâs products include blood bank screening products and quick diagnostic products. And the Company also provides platform services.

Sector

Biotechnology & Medical Research

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
PCL, INC.	-72.11%	3.88Cr
EXACT SCIENCES CORPORATION	-43.30%	827.62Cr
GUARDANT HEALTH, INC.	+7.54%	361.72Cr
IOVANCE BIOTHERAPEUTICS, INC.	+0.37%	224.15Cr
BGI GENOMICS CO., LTD.	-24.94%	194.49Cr
VERACYTE, INC.	-16.61%	172.31Cr
MARAVAI LIFESCIENCES HOLDINGS, INC.	+7.94%	96Cr
CAREDX, INC	+19.92%	73Cr
SEEGENE, INC.	-11.57%	69Cr
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-32.86%	48Cr

Bio Diagnostics & Testing